Neurolite (Bicisate Dihydrochloride)

Bicisate Dihydrochloride, the active ingredient in Neurolite, is a drug presented as an intravenous solution for administration. Public information on its specific therapeutic class and approved uses is limited, and the product is marketed within the European Union.\n\nGNH India supplies Neurolite as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Neurolite (Bicisate Dihydrochloride) is listed without publicly disclosed specific therapeutic indications.\n\n- Approved indication: Not publicly disclosed\n- Therapeutic area: Not specified\n- Clinical use: Not established

Common Side Effects:\n- Not publicly disclosed\n\nSerious or Rare Side Effects:\n- Not publicly disclosed

Neurolite should be used only under the supervision of a qualified prescriber, with attention to patient‑specific factors.\n\n- Dose determination: Set by prescribing clinician based on individual patient needs\n- Renal function: Assess before initiating therapy\n- Hepatic function: Monitor during treatment\n- Allergy: Verify no known hypersensitivity to Bicisate Dihydrochloride or excipients\n- Store at ambient temperature: Keep in original container, protect from moisture and direct sunlight

Neurolite may have drug interactions that are not yet fully characterized in publicly available sources. Clinicians should review patient medication profiles carefully.\n\nMajor Interactions (Avoid):\n- Not identified in current literature\n\nModerate Interactions (Monitor Closely):\n- Not identified in current literature